Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

Increasing number of product approvals by regulatory authorities for the treatment of cancer is expected to drive growth of the subcutaneous drug delivery market. For instance, in February 2019, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window I think that ...

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. Aside from the $750 million upfront payment, the deal also ...

MAINZ, Germany, & MAHWAH, N.J.--(BUSINESS WIRE)--SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, and KORU Medical Systems (NASDAQ: KRMD), a leading medical ...

Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. For $20 million upfront, ...

Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...

TOKYO and CAMBRIDGE, Mass., Nov 28, 2025 - (JCN Newswire) - - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB ...

Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...